Eidos Therapeutics Inc (EIDX)

122.21 0.00 (0.00%)
Real-time Cboe USD Disclaimer

Eidos Therapeutics Inc Company Profile

Industry
-
Sector
-
Employees
70
Equity Type
ORD
Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in phase 3 clinical trial, is an orally administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was incorporated in 2013 and is based in Palo Alto, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma, Inc.
Contact Information
Address
Palo Alto,94104 United States
Phone
415 887 1471
Fax
-
Web
https://

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.